Our results therefore await validation in larger cohorts, and further investigation is needed to determine how well CSF lipids differentiate NMOSD from progressive MS and other neuroinflammatory, demyelinating diseases such as myelin oligodendrocyte glycoprotein antibody-associated disease. The gene discussed is MOG; the disease is myeloid sarcoma.